CT texture analysis of primary esophageal tumors may be a potential imaging biomarker, helping determine the effectiveness of chemotherapy.
CT texture analysis of primary esophageal tumors may be a potential imaging biomarker, helping physicians determine the effectiveness of neoadjuvant chemotherapy, according to a presentation at the 2013 Cancer Imaging and Radiation Therapy Symposium in Orlando, Fla.
To establish a possible prognostic factor in patients with primary esophageal cancer, researchers in the United Kingdom identified 31 patients from Guy's and St. Thomas' NHS Foundation Trust and King's College Hospital NHS Foundation Trust who had localized resectable esophageal cancer and who had received neoadjuvant chemotherapy for esophageal cancer between 2007 and 2010.
Twenty-two patients had adenocarcinoma and nine had squamous cell carcinoma (SCC). The group comprised one patient at stage I, 12 at stage II, 17 at stage III, and one at stage IV. All had received platinum and fluorouracil-based chemotherapy followed by surgery. Eleven patients received adjuvant therapy. Median follow-up was 21.9 months.
Tumor texture analysis was performed using proprietary software (TexRAD, University of Sussex) on staging and post-chemotherapy exams. The texture parameters were mean-grey level intensity (MGI), entropy, uniformity, kurtosis, skewness, and standard deviation with histogram (SDH), and were derived for four filter values to highlight structures of different spatial width: 1.0 (fine texture), 1.5 to 2.0 (medium), and 2.5 (course).
A subgroup of 26 patients was grouped as responders (11) and non-responders (15). Among the responders, five were complete and six were partial.
The researchers found that primary tumors became more homogenous following chemotherapy, as entropy decreased and uniformity increased. Smaller change in skewness following chemotherapy was a significant prognostic factor.
Median overall survival was 36.1 months versus 11.1 months. Lower baseline entropy and lower post-treatment MGI were also associated with improved survival, although they demonstrated only a trend toward significance.
The researchers concluded that CT texture analysis has the potential to be a prognostic biomarker following neoadjuvant therapy in esophageal cancer. Connie Yip, MD, the lead study author and a clinical research fellow at King's College and an associate consultant in radiation oncology at the National Cancer Centre, Singapore, said that although the study was small, the tumoral texture features could be valuable in assessing chemotherapy effectiveness. "As a biomarker for treatment efficacy, this technique could save patients from unnecessary surgery and provide more definitive guidance in developing patient treatment plans with improved outcomes."
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can Photon-Counting CT be an Alternative to MRI for Assessing Liver Fat Fraction?
March 21st 2025Photon-counting CT fat fraction evaluation offered a maximum sensitivity of 81 percent for detecting steatosis and had a 91 percent ICC agreement with MRI proton density fat fraction assessment, according to new prospective research.